Squarepoint
ARCT icon

Squarepoint’s Arcturus Therapeutics ARCT Stock Holding History

Squarepoint’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,000
Closed -$1.01M – 4027
2024
Q1 		$1.01M Buy
+30,000
New +$1.06M ﹤0.01% 2580

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Squarepoint's ARCT Position: Q2 2026 in Review

Squarepoint increased its Arcturus Therapeutics (ARCT) stake by 265% in Q2 2026, buying an estimated $288K and bringing the position to 50,253 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #3722.

Squarepoint first reported a position in ARCT in Q4 2016 and has held it in 14 quarters since. The position peaked at $763K in Q3 2024. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Squarepoint held 50,253 shares of Arcturus Therapeutics worth $338K as of Q2 2026.
  • Squarepoint bought 36,479 Arcturus Therapeutics shares in Q2 2026, an estimated $288K.
  • Arcturus Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3722 holding.
  • Squarepoint first reported a position in Arcturus Therapeutics in Q4 2016 and has held it in 14 quarters since.
  • Squarepoint's Arcturus Therapeutics position peaked at $763K in Q3 2024.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.